https://sporbahisleri.livejournal.com https://wakelet.com/@SporBahisleri67459 https://theomnibuzz.com/author/sporbahisleri/ https://lessons.drawspace.com/profile/322207/sporbahisleri/workflow https://writeupcafe.com/profile/sporbahisleri/ http://www.pearltrees.com/sporbahisleri https://pharmahub.org/members/26874/blog https://www.zupyak.com/u/Spor-Bahisleri/ https://www.metroflog.co/sporbahisleri https://www.fuzia.com/fz/spor-bahisleri https://tr.pinterest.com/sporbahislerim/ https://my.getjealous.com/sporbahisleri https://sporbahisleri.contently.com https://hubpages.com/@sporbahisleri https://www.tumblr.com/sporbahisleri https://hub.docker.com/u/sporbahislerim https://betsiteleri.blogfree.net https://betsiteleri.amebaownd.com https://sporbahisleri.pixnet.net/blog https://betsiteleri.seesaa.net https://betsiteleri.threadless.com https://betsiteleri.neocities.org https://bahissiteleri.localinfo.jp https://betsiteleri.shopinfo.jp https://teletype.in/@betsiteleri https://ubl.xml.org/users/sporbahisleri https://betsiteleri.educatorpages.com https://betsiteleri.onlc.fr https://sporbahisleri.gumroad.com
Vagif M Ibraghimov Author
Subjects of specialization
Affiliation
dialysis
National Research Medical Center Nur-sultan, Kazakhstan
Mekenbaeva R.T is a MD, professor at National Research Medical Center Nur-sultan, Kazakhstan.
Mekenbaeva R.T is a MD, professor at National Research Medical Center Nur-sultan, Kazakhstan.
Annual Meeting Abstract Open Access
Author(s): Vagif M Ibraghimov
Statement of the Problem: The formation of diabetic nephropathy (DN) in patients with diabetes mellitus (DM) type 2 includes stages from preclinical structural changes in kidney tissue in the first years of the disease to diffuse or nodular glomerulosclerosis after 15-20 years of DM. It was found that microalbuminuria is not first and not most specific sign of DN in DM. These facts became the prerequisite for the search of earlier preclinical markers of structural changes in kidney in type 2 DM. The purpose of the study is to develop the method of personalized treatment of DN in DM type 2, which provides for personalized use of hypoglycemic drugs based on dominant clinical problem and predictive urinary proteomic profile. Methodology & Theoretical Orientation: Patients with DM type ... view moreĀ»